Novartis Launches Construction of First Radioligand Manufacturing Site in China
Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, has initiated construction on its second manufacturing...
NYSE: NVS
Novartis’s Scemblix STAMP Inhibitor for CML Accepted for Review by China’s NMPA
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has had its market filing for Scemblix (asciminib)...
Novartis Moves Toward Full Ownership of MorphoSys with Shareholder Squeeze-Out
Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, is proceeding to fully acquire MorphoSys AG...
Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...
Novartis’ Fabhalta Shows Promise in Late-Stage C3 Glomerulopathy Trial
Novartis AG (NYSE: NVS), a leading Swiss pharmaceutical company, last week announced positive preliminary data...
Novartis’ Atrasentan Shows Significant Reduction in Proteinuria in IgA Nephropathy Trial
Novartis AG (NYSE: NVS), a Swiss pharmaceutical company, last week presented interim results for the...
Novartis Shakes Up Executive Suite with Appointments and Transitions
The president of Novartis (NYSE: NVS)’ International Business Unit has this week declared a series...
Novartis Inks Deal to Acquire Mariana Oncology, Bolstering Radioligand Therapy Portfolio
Swiss pharmaceutical giant Novartis (NYSE: NVS) is poised to expand its oncology portfolio by acquiring...
Novartis’s Iptacopan (Fabhalta) Receives Marketing Approval in China for PNH Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received marketing approval from China for its iptacopan...
Novartis Receives Positive Interim Results for Antimalarial Coartem in Infants
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced interim results from a Phase II/III clinical...
Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...
Novartis’s Lutathera Secures FDA Approval for Pediatric Gastroenteropancreatic NETs
The US Food and Drug Administration (FDA) has granted regulatory approval to Novartis (NYSE: NVS)...
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant...
Novartis’s Kesimpta Shows Sustained Efficacy in 6-Year Relapsing MS Study
Swiss pharmaceutical giant Novartis (NYSE: NVS) has this week unveiled six-year efficacy data for its...
Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...
Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value
Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...
Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients
Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...
EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion
AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...
Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...